1. Which of the following correctly identifies the structural feature that defines a catecholamine and lists all six catecholamine agents covered in this module?
A) A catecholamine is defined by the presence of a catechol nucleus (benzene ring with hydroxyl groups at positions 3 and 4, constituting ortho-dihydroxybenzene) plus an ethylamine side chain at position 1; the six clinically relevant catecholamine direct-acting adrenergic agonists are: epinephrine (endogenous adrenal medullary hormone), norepinephrine (endogenous postganglionic sympathetic neurotransmitter), dopamine (biosynthetic precursor of NE and endogenous CNS neurotransmitter), dobutamine (synthetic catecholamine designed for selective inotropic support), isoproterenol (synthetic catecholamine with pure non-selective beta agonist activity), and fenoldopam (synthetic catecholamine with selective D1 dopamine receptor agonism); all six share the catechol ring structure making them substrates for COMT degradation and explaining their poor oral bioavailability and short plasma half-lives of 1-3 minutes.
B) A catecholamine is defined by the presence of a single hydroxyl group on an aromatic benzene ring plus an ethylamine side chain; by this definition, phenylephrine (3-hydroxyl only), ephedrine (no ring hydroxyl), and dopamine all qualify as catecholamines; the catechol-ring distinction from non-catecholamines is only relevant for CNS penetration (catecholamines penetrate the BBB while non-catecholamines do not) and has no bearing on oral bioavailability or metabolic degradation pathways.
C) Catecholamines are defined by their endogenous origin in the adrenal medulla -- the six clinically used catecholamines are all derived from chromaffin cell secretion (epinephrine, norepinephrine, dopamine, DOPA, metanephrine, and normetanephrine); synthetic analogs such as dobutamine, isoproterenol, and fenoldopam are not classified as catecholamines because they are not produced by chromaffin cells; the distinction between catecholamine and non-catecholamine is therefore based on biosynthetic origin rather than chemical structure.
D) A catecholamine requires both the catechol ring AND a methyl group on the nitrogen of the ethylamine side chain -- only epinephrine (N-methylated) qualifies as a true catecholamine; norepinephrine (no N-methyl group) and dopamine (no side-chain hydroxyl, no N-methyl) are classified as catecholamine precursors rather than true catecholamines; isoproterenol (N-isopropyl substitution) is a false catecholamine because the N-isopropyl group is structurally incompatible with the catecholamine definition.
E) The catecholamine class is defined by high potency at beta-adrenergic receptors -- all catecholamines are full beta agonists; non-catecholamines (phenylephrine, ephedrine, amphetamine) are exclusively alpha agonists or indirect sympathomimetics; fenoldopam is classified as a non-catecholamine because it does not activate beta receptors despite having the catechol ring structure.
ANSWER: A
Rationale:
Catecholamines are defined by two structural requirements: (1) A catechol nucleus -- a benzene ring with hydroxyl groups at both the 3 and 4 positions (ortho-dihydroxybenzene); the ortho configuration of both hydroxyls is required (a single hydroxyl, as in phenylephrine, does not constitute a catechol); (2) An ethylamine side chain at position 1 of the ring. The catechol ring makes these compounds substrates for COMT (which O-methylates the 3-hydroxyl), and the polar hydroxyl groups reduce oral bioavailability through first-pass degradation and reduce CNS penetration. The six clinical catecholamines in this module: epinephrine (endogenous adrenal hormone; N-methylated NE), norepinephrine (endogenous postganglionic sympathetic neurotransmitter), dopamine (NE biosynthetic precursor; endogenous CNS neurotransmitter), dobutamine (synthetic racemic catecholamine; selective beta-1 inotrope), isoproterenol (synthetic; N-isopropyl substituted; pure non-selective beta agonist), and fenoldopam (synthetic; selective D1 receptor agonist). All share: MAO/COMT metabolic sensitivity, plasma half-lives of 1-3 minutes, mandatory IV administration in clinical use, and chemical instability at alkaline pH and with oxidizing agents.
Option B: Option B is incorrect: a catecholamine is not defined by a single hydroxyl group on a benzene ring; the defining feature is the catechol ring — specifically 3,4-dihydroxybenzene (two adjacent hydroxyl groups at positions 3 and 4); phenylephrine has only one ring hydroxyl and is therefore not a catecholamine, which is exactly why it is orally bioavailable and has a longer duration of action than true catecholamines.
Option C: Option C is incorrect: catecholamines are not defined by their origin in the adrenal medulla; the classification is purely structural — any compound containing the catechol ring (3,4-dihydroxybenzene) plus an ethylamine side chain is a catecholamine regardless of its origin; dobutamine and isoproterenol are synthetic catecholamines never produced by the adrenal medulla but are pharmacologically classified as catecholamines.
Option D: Option D is incorrect: N-methylation is not a defining feature of the catecholamine class; norepinephrine, dopamine, and isoproterenol are all catecholamines without an N-methyl group; N-methylation (present on epinephrine) affects receptor selectivity (increasing beta-2 affinity) but does not define membership in the catecholamine structural class, which is determined entirely by the catechol ring.
Option E: Option E is incorrect: catecholamines are not defined by high potency at beta-adrenergic receptors; the classification is structural, not pharmacodynamic; phenylephrine is a potent alpha-1 agonist but is not a catecholamine because it lacks the 4-hydroxyl group on the catechol ring; conversely, isoproterenol is a catecholamine with high beta potency but low alpha potency — potency at any specific receptor subtype does not determine catecholamine classification.
2. Which of the following correctly identifies the receptor binding profile of epinephrine and explains how its dose-dependent hemodynamic effects are explained by differential receptor affinity?
A) Epinephrine activates only alpha-1 and beta-1 adrenergic receptors -- it has no beta-2 activity; the wide pulse pressure seen with low-dose epinephrine results from beta-1-mediated increased stroke volume (widened systolic pressure) and alpha-1-mediated venoconstriction (reduced venous compliance, raising diastolic pressure); the dose-dependent hemodynamic shift is from pure beta-1 inotropy at low doses to combined alpha-1 plus beta-1 at high doses without any beta-2 component.
B) Epinephrine does not have dose-dependent receptor selectivity -- it activates alpha-1, alpha-2, beta-1, beta-2, and beta-3 receptors equally at all doses; the apparent hemodynamic differences between low and high doses reflect only the saturation of downstream signaling pathways (G proteins become limiting at high doses), not any differential receptor occupancy; the concept of dose-dependent receptor selectivity is a pharmacological myth.
C) Epinephrine activates alpha-1, alpha-2, beta-1, beta-2, and beta-3 receptors with high potency and is the prototypic non-selective adrenergic agonist; at low doses (0.01-0.05 mcg/kg/min), beta-2-mediated vasodilation in skeletal muscle and splanchnic beds predominates (Gs-cAMP-MLCK inhibition in vascular smooth muscle), raising systolic pressure from increased cardiac output while diastolic pressure may fall from peripheral vasodilation, widening pulse pressure; at higher doses (greater than 0.1 mcg/kg/min), alpha-1-mediated vasoconstriction (Gq-IP3-calcium-MLCK activation) becomes dominant, overriding beta-2 vasodilation and raising both systolic and diastolic pressure, increasing SVR; at very high doses, intense alpha-1 vasoconstriction raises blood pressure so markedly that baroreceptor-mediated reflex vagal bradycardia can override direct beta-1 chronotropic stimulation; the dose-dependent hemodynamic signature reflects the relative potency and tissue distribution of these receptor subtypes at different plasma concentrations.
D) Epinephrine is a partial agonist at beta-2 receptors and a full agonist at alpha-1 and beta-1 receptors -- the partial beta-2 agonism explains why low-dose epinephrine produces less bronchodilation than salbutamol (a full beta-2 agonist); at high doses, epinephrine achieves full beta-2 occupancy and produces maximal bronchodilation equivalent to salbutamol; the dose-dependent vascular hemodynamics are explained entirely by alpha-1 saturation kinetics rather than differential beta-2 contribution.
E) Epinephrine activates alpha-2, beta-1, and beta-3 receptors but not alpha-1 or beta-2; the vasoconstriction seen at high doses is from alpha-2 receptor activation on vascular smooth muscle (postsynaptic alpha-2 vasoconstriction); the bronchodilation is from beta-3 receptor activation on bronchial smooth muscle; alpha-1 and beta-2 receptors in the vasculature and bronchi are not epinephrine targets.
ANSWER: C
Rationale:
Epinephrine is the prototypic non-selective adrenergic agonist, activating alpha-1, alpha-2, beta-1, beta-2, and beta-3 receptors with high potency. The dose-dependent hemodynamics reflect the differential tissue distribution and affinity of these receptor subtypes. At low doses, the beta-2 receptors on skeletal muscle arterioles and splanchnic vasculature (Gs-cAMP -- inhibiting MLCK via PKA phosphorylation, activating BKCa channels) produce vasodilation; simultaneously, beta-1 cardiac activation increases heart rate and contractility, raising cardiac output and systolic pressure; the net effect is increased systolic pressure with potentially unchanged or decreased diastolic pressure (from peripheral vasodilation) -- the classic widened pulse pressure of low-dose epinephrine. At high doses, alpha-1 receptor activation (Gq-IP3-Ca2+-MLCK) on both arterioles and veins overrides beta-2 vasodilation; both systolic and diastolic pressure rise markedly; SVR increases substantially; at very high doses, baroreceptor reflexes (detecting the marked BP increase) generate intense vagal output that can produce net bradycardia despite direct beta-1 SA node stimulation. Beta-3 receptors in brown adipose tissue and bladder are also activated but are less hemodynamically significant than the vascular and cardiac receptor effects.
Option A: Option A is incorrect: epinephrine does have significant beta-2 activity — beta-2 receptor activation is responsible for bronchodilation (the basis for epinephrine's use in anaphylaxis and asthma), skeletal muscle vasodilation (producing the wide pulse pressure at low doses), and mast cell stabilization; absence of beta-2 activity would make epinephrine pharmacologically equivalent to norepinephrine, which it is not.
Option B: Option B is incorrect: epinephrine does have dose-dependent receptor selectivity; at low doses (0.01-0.05 mcg/kg/min), beta-1 and beta-2 effects predominate over alpha-1 because beta receptors have higher affinity for epinephrine than alpha-1 receptors at these concentrations; at higher doses, alpha-1 receptor occupancy increases sufficiently to produce net vasoconstriction that overrides beta-2 vasodilation; this dose-dependent profile is clinically important and well-established.
Option D: Option D is incorrect: epinephrine is a full agonist at beta-2 receptors, not a partial agonist; its bronchodilatory potency at beta-2 receptors is high and produces maximal smooth muscle relaxation; the dose-dependent hemodynamic profile of epinephrine reflects differential receptor affinities and occupancy at different plasma concentrations, not partial agonism at any receptor subtype.
Option E: Option E is incorrect: epinephrine does activate alpha-1 receptors (at higher doses, producing vasoconstriction) and beta-2 receptors (at lower doses, producing bronchodilation and vasodilation); it does not selectively activate alpha-2, beta-3 while sparing alpha-1 and beta-2; this description inverts the established receptor profile of epinephrine and misattributes vasoconstriction to alpha-2 postsynaptic activation rather than alpha-1.
3. Norepinephrine differs critically from epinephrine in its receptor binding profile. Which of the following correctly identifies the key pharmacological distinction and its hemodynamic consequence?
A) Norepinephrine differs from epinephrine primarily by having a methyl group on the nitrogen (epinephrine has an N-methyl group; norepinephrine does not); this N-methyl group is responsible for epinephrine's beta-2 activity, which norepinephrine lacks; therefore, norepinephrine activates alpha-1, alpha-2, and beta-1 receptors but has substantially less beta-2 activity than epinephrine; the hemodynamic consequence is that norepinephrine produces uniformly vasoconstrictive effects (no opposing beta-2 vasodilation), raising both systolic and diastolic pressure with a tendency for reflex bradycardia rather than tachycardia, and without the dose-dependent hemodynamic shift seen with epinephrine.
B) Norepinephrine is identical to epinephrine in its receptor profile -- both activate alpha-1, alpha-2, beta-1, and beta-2 equally; the hemodynamic difference between them is entirely pharmacokinetic: norepinephrine has a shorter plasma half-life (30 seconds versus 2 minutes for epinephrine) and is therefore less potent on a per-dose basis; at equal plasma concentrations, norepinephrine and epinephrine produce identical hemodynamic effects.
C) Norepinephrine lacks the N-methyl group present on epinephrine, and this structural difference confers substantially less beta-2 receptor affinity; norepinephrine activates alpha-1 (potent), alpha-2 (moderate), and beta-1 (moderate) receptors but has minimal clinically significant beta-2 activity at therapeutic doses; the hemodynamic consequence: NE produces intense, uniform peripheral vasoconstriction (alpha-1 dominant, no opposing beta-2 vasodilation) raising both systolic and diastolic pressure; heart rate often decreases reflexly from baroreceptor activation (despite direct beta-1 chronotropic stimulation, the baroreceptor reflex response to markedly elevated BP increases vagal tone sufficiently to cause net bradycardia); cardiac output may decrease (increased afterload from alpha-1 vasoconstriction without significant beta-2 vasodilation) or remain stable depending on the balance with beta-1 inotropy; this hemodynamic profile makes NE ideal for vasodilatory/distributive shock (low SVR, often adequate CO).
D) The key difference between norepinephrine and epinephrine is that norepinephrine is a selective beta-1 agonist (like dobutamine) while epinephrine is a selective alpha-1 agonist (like phenylephrine); the receptor selectivity was determined in 1948 by Ahlquist using potency rank-order studies; norepinephrine's beta-1 selectivity explains why it is used as an inotrope in cardiogenic shock while epinephrine is used as a vasopressor in septic shock.
E) Norepinephrine differs from epinephrine by having an additional alpha-2 receptor agonist activity that epinephrine lacks; the presynaptic alpha-2 autoreceptor activation by norepinephrine provides a self-limiting negative feedback that prevents excessive vasoconstriction during NE infusion; epinephrine, which does not activate presynaptic alpha-2 autoreceptors, produces unregulated alpha-1 vasoconstriction that is why epinephrine produces more severe hypertension than norepinephrine at equivalent doses.
ANSWER: B
Rationale:
The structural distinction between epinephrine and norepinephrine is the N-methyl group: epinephrine has a methyl group on the terminal amine of the ethylamine side chain while norepinephrine does not (norEPINEPHRINE = desmethyl-epinephrine; the nor- prefix in pharmacology denotes the desmethyl analog). This N-methyl group is responsible for epinephrine's substantially greater beta-2 receptor affinity -- the N-methyl substituent increases the fit between the amine group and the beta-2 receptor binding site; norepinephrine's unsubstituted primary amine fits the beta-2 binding site much less well, resulting in dramatically lower beta-2 potency. Hemodynamic consequences: NE activates alpha-1 (potent, producing intense vasoconstriction), alpha-2 (moderate), and beta-1 (moderate) but has minimal beta-2 activity at clinical doses; the absence of significant beta-2 vasodilatory activity means NE's net vascular effect is uniformly vasoconstrictive -- both systolic and diastolic pressure rise, SVR increases markedly; the baroreceptor reflex to rising BP increases vagal tone sufficiently to cause net heart rate decrease despite beta-1 stimulation; cardiac output may fall (increased afterload) or remain stable. This profile -- vasopressor without significant vasodilation -- is ideal for distributive/vasodilatory shock (septic shock, neurogenic shock) where the primary deficit is low SVR. Epinephrine's additional beta-2 vasodilation at lower doses makes it hemodynamically more complex and less predictable as a pure vasopressor.
Option A: Option A is incorrect in its framing: it states that NE differs from epinephrine by having an N-methyl group — this is backwards; epinephrine has the N-methyl group and NE does not; Option A then correctly identifies that the N-methyl group confers greater beta-2 affinity, but the structural attribution is inverted, making Option A factually incorrect in its core statement about which molecule has the N-methyl group.
Option C: Option C is partially correct in identifying that NE lacks the N-methyl group and has less beta-2 activity than epinephrine; however, it understates NE's beta-1 activity and incorrectly implies NE is primarily useful as a vasopressor through alpha-1 alone; NE has significant beta-1 activity (providing cardiac support alongside vasoconstriction) which distinguishes it from pure alpha-1 agonists like phenylephrine.
Option D: Option D is incorrect: NE is not a selective beta-1 agonist — it activates alpha-1, alpha-2, and beta-1 receptors with high potency; it has minimal but not absent beta-2 activity; describing NE as "selective beta-1" conflates it with dobutamine; similarly, describing epinephrine as "selective alpha-1" is incorrect — epinephrine activates all adrenergic receptor subtypes including substantial beta-2 activity.
Option E: Option E is incorrect: NE does not have additional alpha-2 agonist activity that epinephrine lacks; both NE and epinephrine activate presynaptic alpha-2 autoreceptors; the key structural and pharmacological difference between them is NE's lack of the N-methyl group, which reduces (but does not eliminate) beta-2 receptor affinity; the alpha-2 receptor profile is not meaningfully different between NE and epinephrine.
4. Which of the following correctly identifies the three dose-dependent receptor engagement ranges of dopamine and the dominant pharmacological effect of each range?
A) Dopamine dose ranges: (1) Low dose 1-3 mcg/kg/min: D1 receptor predominance; D1 is Gs-coupled and activates adenylyl cyclase in renal tubular cells and renal/mesenteric vascular smooth muscle; produces renal and splanchnic vasodilation, natriuresis (inhibition of proximal tubule Na+/K+-ATPase and Na+/H+ exchanger), and increased GFR; (2) Intermediate dose 3-10 mcg/kg/min: beta-1 adrenergic receptor activation becomes prominent; produces positive inotropy and chronotropy, increasing cardiac output; dopamine also releases norepinephrine from sympathetic terminals at this range (indirect sympathomimetic effect), augmenting the beta-1 response; (3) High dose greater than 10 mcg/kg/min: alpha-1 adrenergic receptor activation dominates, producing peripheral vasoconstriction, increased SVR, and a hemodynamic profile resembling NE; the renal vasodilatory D1 effects are overridden by alpha-1 vasoconstriction; these ranges are approximate and overlapping with significant individual variability.
B) Dopamine dose ranges: (1) Low dose 1-3 mcg/kg/min: beta-1 receptor predominance producing positive inotropy; D1 receptor effects do not occur until intermediate doses; (2) Intermediate dose 3-10 mcg/kg/min: D1 receptor activation producing renal vasodilation -- the "renal dose" range; (3) High dose greater than 10 mcg/kg/min: beta-2 receptor activation producing peripheral vasodilation and hypotension; alpha-1 effects do not occur with dopamine at any dose because dopamine lacks the structural requirements for alpha-1 receptor binding; the hemodynamic shift at high doses from vasopressor to vasodilator is the pharmacological basis for using high-dose dopamine in hypertensive emergencies.
C) Dopamine activates only D1 and D2 receptors -- it does not activate alpha-1 or beta-1 adrenergic receptors directly; the dose-dependent adrenergic effects of dopamine (tachycardia at intermediate doses, vasoconstriction at high doses) are entirely due to indirect effects -- dopamine at all doses stimulates NE release from sympathetic terminals, and the released NE activates adrenergic receptors; the three dose ranges reflect increasing NE release (low dose: minimal NE release; intermediate: moderate NE release producing beta-1 effects; high dose: maximal NE release producing alpha-1 effects).
D) The three dopamine dose ranges and their dominant receptor mechanisms: (1) 1-3 mcg/kg/min: D1 (renal/mesenteric vasodilation, natriuresis); (2) 3-10 mcg/kg/min: beta-1 (inotropy, chronotropy) plus ongoing D1 plus early alpha-1 at the upper end; (3) greater than 10 mcg/kg/min: alpha-1 dominant (vasoconstriction, increased SVR); note that dopamine also has an indirect adrenergic effect at intermediate and high doses by releasing NE from sympathetic nerve terminals, augmenting the direct adrenergic receptor activation; the ranges are clinically approximate with substantial individual pharmacokinetic and pharmacodynamic variability; a patient in shock with depleted sympathetic NE stores may show less beta-1 effect at intermediate doses (less indirect component) while a healthy patient would show a more pronounced indirect response.
E) Dopamine receptor engagement is not dose-dependent -- dopamine activates all three receptor populations (D1, beta-1, alpha-1) simultaneously and equally at all doses; the concept of dose-dependent receptor selectivity was originally proposed in animal studies (rats and dogs) and has been definitively refuted in human pharmacological studies which show that all three receptor types are activated from the lowest clinically used dopamine dose; the dose-range concept persists in textbooks as a teaching simplification but should not be used to guide clinical drug dosing decisions.
ANSWER: D
Rationale:
Dopamine's uniquely complex receptor engagement profile reflects its dose-dependent plasma concentration achieving progressively higher affinity thresholds at three receptor classes. Low-dose range (1-3 mcg/kg/min): D1 receptor Gs-cAMP activation predominates in renal and mesenteric vasculature and renal tubular cells; produces renal/splanchnic vasodilation, increased RBF and GFR, inhibition of proximal tubule Na+/K+-ATPase and Na+/H+ exchanger (natriuresis and diuresis); D2 receptor activation at low doses on presynaptic sympathetic terminals inhibits NE release, also contributing to vasodilation. Intermediate range (3-10 mcg/kg/min): beta-1 receptor activation becomes prominent (direct), producing positive inotropy and chronotropy; dopamine also induces NE release from vesicular stores in sympathetic terminals at this concentration range (indirect mechanism), augmenting beta-1 effects; D1 effects continue; alpha-1 activation begins at the upper end. High-dose range (greater than 10 mcg/kg/min): alpha-1 activation dominates, overriding D1-mediated vasodilation with alpha-1-mediated vasoconstriction; hemodynamic profile increasingly resembles NE infusion. Critical caveat: these ranges are clinically approximate with substantial interpatient variability; the "precise" dose thresholds in pharmacology texts are derived from population averages, and individual patients may show alpha-1 vasoconstriction at doses as low as 5-7 mcg/kg/min or require 15+ mcg/kg/min. Options A and D are both accurate; D adds the clinically important caveat about depleted NE stores modifying the indirect component.
Option A: Option A is partially correct and accurately describes dopamine's dose-dependent receptor activation — D1 at low doses, beta-1 at intermediate, alpha-1 at high doses; however, Option D is the correct answer because it adds the clinically important caveat that the intermediate-dose beta-1 inotropic effects of dopamine depend partly on indirect NE release from sympathetic terminals, which can be unreliable in patients with depleted NE stores (e.g., chronic heart failure).
Option B: Option B is incorrect: it inverts the dose-dependent receptor sequence; beta-1 effects do not predominate at low doses (1-3 mcg/kg/min) — D1 effects predominate at low doses; D1 receptor activation produces renal and mesenteric vasodilation (and was the basis for the now-abandoned "renal dose dopamine" concept); beta-1 inotropic effects predominate at intermediate doses (3-10 mcg/kg/min).
Option C: Option C is incorrect: dopamine does activate alpha-1 and beta-1 adrenergic receptors directly in addition to D1 and D2 dopaminergic receptors; at intermediate doses, direct beta-1 receptor activation and indirect NE release both contribute to inotropic effects; at high doses, direct alpha-1 activation produces vasoconstriction; the statement that all adrenergic effects are entirely indirect (via NE release) is inaccurate — dopamine activates adrenergic receptors both directly and indirectly.
Option E: Option E is incorrect: dopamine receptor engagement is dose-dependent; D1 receptors have higher affinity for dopamine and are engaged preferentially at low plasma concentrations; higher doses progressively recruit beta-1 and then alpha-1 receptors as plasma concentrations rise; this dose-dependent receptor hierarchy is the pharmacological basis for dopamine's variable hemodynamic effects across its dose range and is a fundamental principle of dopamine pharmacology.
5. Dobutamine is a synthetic catecholamine designed to provide selective inotropic support. Which of the following correctly identifies the structural basis for dobutamine's net receptor selectivity profile and distinguishes it from dopamine?
A) Dobutamine achieves beta-1 selectivity through a bulky N-substituent (the para-hydroxyphenyl ethyl group on the terminal nitrogen) that sterically prevents binding to alpha-1 and beta-2 receptors while fitting optimally in the beta-1 binding site; this steric mechanism of selectivity is analogous to that of metoprolol (beta-1 selective blocker) and explains why dobutamine, like metoprolol, has dose-dependent selectivity that is lost at very high doses.
B) Dobutamine is a racemic mixture: the (-)-enantiomer is an alpha-1 agonist and beta-1 agonist; the (+)-enantiomer is an alpha-1 antagonist and beta-1 agonist; the opposing alpha-1 effects of the two enantiomers cancel each other out, while the beta-1 agonist activity from both enantiomers is additive; the net pharmacological result is predominantly beta-1 agonism with minimal net alpha-1 activity; dobutamine also has moderate beta-2 agonism (both enantiomers) contributing mild peripheral vasodilation; unlike dopamine, dobutamine does not activate dopaminergic D1 or D2 receptors and does not release NE from sympathetic terminals (no indirect adrenergic mechanism); dobutamine's inotropic effect therefore persists even in sympathetically depleted patients where dopamine's indirect mechanism would be impaired.
C) Dobutamine achieves its net beta-1 selective profile because it is metabolized in the myocardium to a beta-1-selective active metabolite (3-O-methyldobutamine) by cardiac COMT; in peripheral vascular tissue, COMT metabolizes dobutamine to an alpha-1-blocking metabolite; the tissue-specific COMT metabolism produces organ-selective beta-1 cardiac stimulation with peripheral alpha-1 blockade -- explaining why dobutamine increases cardiac output while simultaneously reducing peripheral vascular resistance; dopamine lacks this tissue-specific COMT metabolism pattern.
D) Dobutamine is identical to dopamine in its receptor mechanism -- both are beta-1 selective catecholamines that act primarily by releasing NE from sympathetic terminals; the structural difference between dobutamine and dopamine (the para-hydroxyphenyl ethyl substituent on the nitrogen versus dopamine's unsubstituted amine) determines only their pharmacokinetic profiles (half-life, volume of distribution) without any difference in receptor selectivity or mechanism of action.
E) Dobutamine is a prodrug that is enzymatically converted to dopamine in cardiac tissue by decarboxylation of the catecholamine side chain; the dobutamine-to-dopamine conversion in the myocardium produces local high concentrations of dopamine that activate cardiac D1 receptors (which are Gs-coupled) increasing cAMP and producing inotropy; peripheral dobutamine is not converted to dopamine because peripheral decarboxylase enzyme is inhibited by the bulky N-substituent of dobutamine; this cardiac-selective D1 activation mechanism explains dobutamine's selective inotropic profile without peripheral vasoconstriction.
ANSWER: B
Rationale:
Dobutamine's net receptor selectivity profile arises from an elegant enantiomeric mechanism. It is formulated as a racemate -- a 50:50 mixture of two stereoisomers with opposing alpha-1 properties: (-)-dobutamine enantiomer: alpha-1 agonist + beta-1 agonist; (+)-dobutamine enantiomer: alpha-1 antagonist + beta-1 agonist; both enantiomers have beta-1 agonist activity (additive when combined) and both have moderate beta-2 agonist activity; the alpha-1 agonism of one enantiomer and alpha-1 antagonism of the other cancel each other out, leaving a net receptor profile of: beta-1 agonism (dominant, positive inotropy and chronotropy) + beta-2 agonism (mild, peripheral vasodilation reducing SVR and PCWP) + approximately zero net alpha-1 activity. This produces the characteristic dobutamine hemodynamic signature: increased cardiac output, decreased filling pressures (PCWP), modest heart rate increase, and stable or slightly decreased MAP (from the mild beta-2 vasodilation). Distinctions from dopamine: dobutamine does not activate D1 or D2 dopaminergic receptors; dobutamine does not induce NE release from sympathetic terminals (no indirect mechanism) -- its inotropic effect is entirely receptor-direct and therefore persists in catecholamine-depleted patients (e.g., patients on chronic sympatholytic therapy, severely heart-failing patients with depleted cardiac NE stores); dopamine's intermediate-dose inotropic effects partly depend on indirect NE release.
Option A: Option A is partially correct in identifying the bulky N-substituent as the structural basis for dobutamine's receptor selectivity; however, this mechanism alone overstates the simplicity of dobutamine's selectivity; dobutamine is a racemic mixture where the (+)-enantiomer is a beta-1 and beta-2 agonist and the (-)-enantiomer is an alpha-1 antagonist; the net clinical effect is beta-1 dominant activity because the alpha-1 effects of the (+)-enantiomer are antagonized by the (-)-enantiomer; Option B correctly describes this stereochemical mechanism.
Option C: Option C is incorrect: dobutamine does not achieve beta-1 selectivity through metabolism to a beta-1-selective active metabolite by cardiac COMT; dobutamine's selectivity is determined by the structural properties of the parent molecule (specifically its stereochemistry); while dobutamine is metabolized by COMT, this does not produce a pharmacologically active beta-1-selective metabolite that accounts for its clinical receptor profile.
Option D: Option D is incorrect: dobutamine does not act primarily by releasing NE from sympathetic terminals; it is a direct-acting catecholamine agonist that activates adrenergic receptors directly; unlike dopamine at intermediate doses (which has a substantial indirect NE-releasing component), dobutamine's inotropic effects are direct and do not depend on intact sympathetic nerve terminals or NE stores — an important clinical distinction in patients with chronic heart failure.
Option E: Option E is incorrect: dobutamine is not a prodrug that is converted to dopamine; it is a structurally distinct synthetic catecholamine that acts directly on adrenergic receptors without requiring metabolic activation; dobutamine and dopamine have different structures, different receptor profiles, and different clinical pharmacology; they are not interconvertible in vivo.
6. Isoproterenol is described as having essentially pure non-selective beta agonist activity. Which of the following correctly identifies the structural basis for isoproterenol's receptor selectivity and the hemodynamic consequence of its exclusive beta-1 and beta-2 activity without any alpha activity?
A) Isoproterenol is a synthetic catecholamine with an N-isopropyl substitution on the terminal amine of the ethylamine side chain; this bulky N-isopropyl group dramatically increases affinity for beta-1 and beta-2 receptors (which accommodate larger N-substituents in their binding sites) while essentially abolishing alpha-1 and alpha-2 receptor binding (which require smaller or no N-substituents); the result is essentially pure beta-1 plus beta-2 agonism without any alpha receptor activity; hemodynamic consequences of this pure beta activation: beta-1 effects (marked positive chronotropy and inotropy, increasing cardiac output substantially and increasing myocardial oxygen consumption); beta-2 effects (peripheral vasodilation in skeletal muscle and splanchnic beds, decreasing SVR and diastolic blood pressure); combined effect: heart rate increases markedly, cardiac output increases, SVR falls, diastolic blood pressure falls (from beta-2 vasodilation), systolic blood pressure may rise modestly or remain stable, and mean arterial pressure may decrease despite increased cardiac output (because the fall in diastolic pressure can outweigh the rise in systolic); this hemodynamic profile -- increased CO with decreased SVR and falling MAP -- makes isoproterenol useful for chronotropy/inotropy but unsuitable as a vasopressor.
B) Isoproterenol achieves pure beta selectivity because it contains no catechol ring -- the absence of the catechol ring prevents binding to alpha receptors which require the catechol hydroxyl groups for high-affinity binding; the N-isopropyl substitution additionally promotes beta receptor affinity; since alpha receptors cannot bind isoproterenol, only beta-1 and beta-2 responses occur; the hemodynamic profile is therefore purely beta-mediated: increased HR and CO (beta-1) plus vasodilation (beta-2).
C) Isoproterenol's lack of alpha activity reflects its binding only to dopaminergic D1 receptors in the vasculature, not adrenergic alpha or beta receptors; D1-mediated vasodilation (Gs-cAMP) in peripheral vasculature reduces SVR; cardiac stimulation from isoproterenol is via cardiac D1 receptors (not beta-1 adrenergic receptors); this mechanism distinguishes isoproterenol from dobutamine (which acts on beta-1) and from fenoldopam (which acts on vascular D1 without cardiac D1).
D) The N-isopropyl group on isoproterenol is identical to the N-methyl group on epinephrine (isopropyl and methyl are both alkyl N-substituents with the same pharmacological consequence); both isoproterenol and epinephrine therefore have identical receptor profiles at identical plasma concentrations; the only pharmacological difference between them is isoproterenol's greater potency (10 times more potent than epinephrine on a molar basis) reflecting its greater receptor affinity due to the larger N-isopropyl versus N-methyl group.
E) Isoproterenol is equivalent to a combined simultaneous infusion of a selective beta-1 agonist (dobutamine) plus a selective beta-2 agonist (salbutamol) -- its N-isopropyl substitution gives it exactly equal affinity for beta-1 and beta-2 receptors; the hemodynamic result is the arithmetic sum of dobutamine hemodynamics (increased CO, decreased PCWP) and salbutamol hemodynamics (bronchodilation, peripheral vasodilation); at equimolar concentrations, isoproterenol is exactly twice as potent as either dobutamine or salbutamol alone because it activates both beta subtypes simultaneously.
ANSWER: A
Rationale:
The structure-activity relationships of adrenergic agonists reveal how N-substituent size on the ethylamine side chain determines receptor selectivity. Norepinephrine (primary amine, no N-substituent): highest alpha-1 and alpha-2 affinity; moderate beta-1; minimal beta-2. Epinephrine (N-methyl substituent): high alpha-1 and alpha-2; high beta-1; substantial beta-2. Isoproterenol (N-isopropyl substituent): minimal alpha-1 and alpha-2 (the bulky isopropyl group has poor fit in the alpha receptor binding site which accommodates only small N-substituents); very high beta-1 and beta-2 (the beta receptor binding sites accommodate larger N-substituents, and the N-isopropyl group optimizes beta receptor affinity); isoproterenol is the most potent beta agonist in clinical use on a molar basis. Hemodynamic consequences of pure beta (no alpha) activation: marked beta-1 SA node chronotropy (HR can increase to 150-180+ bpm), beta-1 ventricular inotropy (increased CO and SV), beta-2 peripheral vasodilation (decreased SVR, decreased DBP) -- the combination produces increased pulse pressure (elevated SBP from increased CO, decreased DBP from vasodilation), potentially unchanged or decreased MAP despite increased CO (because DBP fall can exceed SBP rise), and markedly increased myocardial oxygen demand with simultaneously decreased coronary perfusion pressure (from falling DBP) -- a dangerous combination in ischemic heart disease. This explains why isoproterenol is avoided in angina (HOCM) and has narrow clinical indications (TdP with bradycardia, EP lab arrhythmia induction, bridge to pacing).
Option B: Option B is incorrect: isoproterenol achieves pure beta selectivity not because it lacks a catechol ring, but because of its large N-isopropyl substituent; isoproterenol does contain the catechol ring (3,4-dihydroxybenzene) — it is a catecholamine; the N-isopropyl group (bulky N-substituent) sterically prevents high-affinity binding to alpha-1 receptors while preserving high affinity for beta receptors; absence of the catechol ring would make it a non-catecholamine, which isoproterenol is not.
Option C: Option C is incorrect: isoproterenol does not activate D1 dopaminergic receptors; it is a pure beta-adrenergic agonist (beta-1 and beta-2) with no significant dopaminergic, alpha-adrenergic, or other receptor activity; the peripheral vasodilation from isoproterenol is beta-2-mediated (Gs-cAMP-PKA-mediated smooth muscle relaxation in skeletal muscle vasculature), not D1-mediated.
Option D: Option D is incorrect: the N-isopropyl group on isoproterenol is not pharmacologically identical to the N-methyl group on epinephrine; the N-isopropyl group is substantially larger and bulkier than the N-methyl group, and this size difference is precisely what determines receptor selectivity; epinephrine with its smaller N-methyl group retains significant alpha-1 activity, while isoproterenol with its large N-isopropyl group has essentially no alpha-1 activity.
Option E: Option E is incorrect: isoproterenol is not pharmacologically equivalent to a combined dobutamine plus salbutamol infusion; while isoproterenol does have both beta-1 and beta-2 activity, its receptor activation profile, potency ratios, and pharmacokinetics differ from a combination of two selective agents; additionally, the clinical effects of isoproterenol (particularly profound tachycardia from combined beta-1 chronotropy and baroreceptor reflex to beta-2 vasodilation) are qualitatively distinct from the additive effects of dobutamine plus a beta-2 agonist.
7. Fenoldopam mesylate is described as a selective D1 dopamine receptor agonist. Which of the following correctly identifies the pharmacological properties that distinguish fenoldopam from dopamine at the receptor level and explains the clinical significance of its receptor selectivity?
A) Fenoldopam and dopamine have identical receptor profiles -- both selectively activate D1 receptors at low doses; fenoldopam differs from dopamine only in its pharmacokinetics (fenoldopam has a longer half-life than dopamine, approximately 15 minutes versus 2 minutes); the clinical advantage of fenoldopam over low-dose dopamine for renal protection is entirely pharmacokinetic (more stable plasma levels from longer half-life) rather than any pharmacodynamic difference.
B) Fenoldopam differs from dopamine in that fenoldopam additionally activates D2 receptors (both D1 and D2) while dopamine at low doses activates only D1; the D2 component of fenoldopam produces presynaptic inhibition of NE release from sympathetic terminals, providing an additional vasodilatory mechanism that dopamine does not have at low doses; this dual D1+D2 mechanism is why fenoldopam is more effective than low-dose dopamine for antihypertensive purposes.
C) Fenoldopam is a selective D1 dopamine receptor agonist with no significant activity at alpha-1, alpha-2, beta-1, or beta-2 adrenergic receptors; this receptor selectivity distinguishes it fundamentally from dopamine, which activates D1 receptors only as part of a broader dose-dependent receptor engagement that also includes beta-1 (at intermediate doses) and alpha-1 (at high doses); fenoldopam therefore provides pure D1-mediated renal and mesenteric vasodilation, natriuresis, and blood pressure reduction without any adrenergic receptor activation -- avoiding the tachycardia (beta-1), vasoconstriction (alpha-1), arrhythmias (beta-1), and prolactin suppression (D2) associated with dopamine infusion; fenoldopam also does not release NE from sympathetic terminals (no indirect adrenergic mechanism).
D) Fenoldopam is selective for D1 over D2 receptors but also has significant alpha-1 agonist activity -- the alpha-1 component of fenoldopam produces renal efferent arteriolar vasoconstriction that increases glomerular hydrostatic pressure and GFR; the renal protective mechanism of fenoldopam in AKI therefore reflects both D1-mediated afferent arteriolar vasodilation (increasing blood flow) and alpha-1-mediated efferent arteriolar constriction (increasing filtration pressure); this dual mechanism is unique to fenoldopam and not shared by dopamine.
E) Fenoldopam activates D1 receptors in the kidney but also activates alpha-2 receptors on sympathetic nerve terminals throughout the body -- the alpha-2 activation produces presynaptic inhibition of NE release, reducing sympathetic tone and contributing to the antihypertensive effect; the reflex tachycardia seen with fenoldopam reflects the loss of sympathetic NE (from alpha-2-mediated suppression) causing baroreceptor-driven tachycardia, not the direct baroreceptor response to vasodilation.
ANSWER: C
Rationale:
The pharmacological distinction between fenoldopam and dopamine is fundamental to understanding their different clinical roles. Dopamine activates multiple receptor classes in a dose-dependent manner: D1 and D2 at low doses, beta-1 at intermediate doses, and alpha-1 at high doses; this means any given dopamine infusion rate activates a mixture of receptor types, making its hemodynamic profile less predictable and less selective. Fenoldopam is a benzazepine D1 receptor agonist with approximately 6-fold greater affinity for D1 over D2; at clinical doses it has no significant activity at alpha-1, alpha-2, beta-1, or beta-2 adrenergic receptors -- a fundamentally different receptor footprint from dopamine. The clinical significance of fenoldopam's D1 selectivity: (1) Renal vasodilation and increased RBF/GFR without any alpha-1-mediated renal vasoconstriction at higher doses; (2) Blood pressure reduction via D1-mediated peripheral vasodilation without the tachycardia of beta-1 activation or the vasoconstriction of alpha-1 activation; (3) No indirect NE release from sympathetic terminals (unlike dopamine at intermediate doses); (4) No D2-mediated adverse effects (nausea/vomiting from area postrema D2 activation, prolactin suppression from pituitary D2 activation, presynaptic NE release inhibition) that dopamine produces at all doses; (5) Preserved efficacy at all infusion rates without the dose-range complexity of dopamine. The reflex tachycardia seen with fenoldopam is a baroreceptor response to vasodilation-mediated BP reduction, not a direct adrenergic receptor effect.
Option A: Option A is incorrect: fenoldopam and low-dose dopamine do not have identical receptor profiles; fenoldopam is a selective D1 agonist with no D2, alpha, or beta receptor activity; dopamine at low doses activates D1 receptors but also has D2 activity (presynaptic inhibition of NE release) and at intermediate doses activates beta-1 and alpha-1 adrenergic receptors; their pharmacokinetics also differ significantly — fenoldopam is an IV infusion with a half-life of approximately 5 minutes, similar to dopamine.
Option B: Option B is incorrect: fenoldopam does not activate D2 receptors; it is a selective D1 agonist; D2 receptor activation by dopamine produces presynaptic inhibition of NE release from sympathetic terminals, nausea/vomiting (via chemoreceptor trigger zone D2 receptors), and endocrine effects (prolactin suppression via pituitary D2 receptors); none of these D2-mediated effects occur with fenoldopam, which is one of its advantages over dopamine.
Option D: Option D is incorrect: fenoldopam does not have significant alpha-1 agonist activity; alpha-1 agonism would produce renal efferent arteriolar vasoconstriction, reducing GFR — the opposite of fenoldopam's renal protective mechanism; fenoldopam's renal benefit derives from D1-mediated afferent arteriolar vasodilation increasing renal blood flow and from D1-mediated natriuretic effects on tubular sodium reabsorption.
Option E: Option E is incorrect: fenoldopam does not activate alpha-2 receptors on sympathetic nerve terminals; it is a selective D1 agonist with no significant alpha-adrenergic receptor activity; alpha-2 presynaptic inhibition of NE release is the mechanism of drugs like clonidine and guanfacine, not fenoldopam; the hypotension and reflex tachycardia from fenoldopam are consequences of D1-mediated vasodilation, not any adrenergic receptor interaction.
8. The route of administration and pharmacokinetic constraints of catecholamines are determined by their chemical structure. Which of the following correctly identifies why all clinical catecholamines require intravenous administration and cannot be given orally for systemic effects?
A) Catecholamines cannot be given orally because they are too large to be absorbed across the gastrointestinal epithelium -- their molecular weight (approximately 180-220 daltons) exceeds the size cutoff for passive absorption from the GI tract; they require parenteral administration because only IV injection allows drug molecules of this size to enter the systemic circulation.
B) Oral catecholamines are rapidly degraded before reaching the systemic circulation through two complementary mechanisms: (1) Intestinal wall COMT (catechol-O-methyltransferase): COMT is expressed on the luminal surface of intestinal epithelial cells and O-methylates the catechol ring of absorbed catecholamines during passage through the gut wall, converting them to pharmacologically inactive O-methylated metabolites (metanephrine from epinephrine, normetanephrine from NE); (2) Hepatic first-pass metabolism by MAO and COMT: catecholamines that survive intestinal COMT are then extracted and metabolized by hepatic MAO-A and COMT during first-pass transit; the combination of gut wall COMT and hepatic first-pass metabolism reduces oral bioavailability to negligible levels for all catecholamines; this is why levodopa (a catechol amino acid, not a catecholamine per se) requires carbidopa (peripheral DOPA decarboxylase inhibitor) to achieve adequate CNS levels -- the same enzymatic barriers apply to catechol-containing compounds broadly.
C) Catecholamines cannot be given orally because they are unstable in the acidic gastric environment -- the catechol ring is hydrolyzed by gastric HCl at pH 1-2, converting the dihydroxybenzene to a benzoquinone that is pharmacologically inactive; this acid instability is why catecholamine IV solutions must be pH-adjusted to slightly acidic pH 3-4 with HCl to prevent the same acid hydrolysis that occurs in the stomach; oral administration even with enteric coating fails because the catechol ring is already irreversibly hydrolyzed in the stomach before any absorption occurs.
D) Oral bioavailability of catecholamines is limited by both intestinal/hepatic first-pass COMT and MAO metabolism AND by the polarity of the catechol ring: the two ring hydroxyl groups (plus the beta-carbon hydroxyl in epinephrine and NE) create a highly polar molecule that is absorbed poorly from the intestinal lumen due to limited passive transcellular diffusion across the lipid bilayer; oral bioavailability for epinephrine, NE, and dopamine is less than 5%; the IM route (particularly into the highly vascularized vastus lateralis for epinephrine in anaphylaxis) achieves faster and more reliable absorption than subcutaneous injection because of greater blood flow at the injection site.
E) Catecholamines can be given orally with acceptable bioavailability -- oral epinephrine tablets have been developed and produce adequate plasma levels for mild anaphylaxis; the reason catecholamines are not routinely given orally is purely regulatory: oral catecholamines were withdrawn from the market in the 1980s due to concerns about cardiovascular side effects from inconsistent absorption, not because of any pharmacokinetic limitation; the EpiPen and other auto-injectors replaced oral catecholamines for non-pharmacokinetic reasons.
ANSWER: D
Rationale:
Oral catecholamine bioavailability is negligible due to multiple pharmacokinetic barriers. (1) Intestinal wall first-pass COMT metabolism: COMT is expressed in intestinal epithelial cells (enterocytes); catecholamines absorbed from the gut lumen are O-methylated during transit through the intestinal wall, converting the pharmacologically active catechol to an inactive O-methylated metabolite before reaching the portal circulation; this gut wall COMT effect is analogous to, and compounds with, the intestinal CYP3A4 first-pass effect that limits oral bioavailability of many drugs. (2) Hepatic first-pass MAO and COMT: catecholamines that survive intestinal COMT are further metabolized by hepatic MAO-A (oxidative deamination) and COMT during first-pass transit through the portal circulation; the combined intestinal + hepatic first-pass effect reduces oral bioavailability of catecholamines to less than 5%. (3) Polarity and poor passive absorption: the two catechol ring hydroxyls plus the beta-carbon hydroxyl (in epinephrine and NE) make these molecules highly polar and water-soluble; poor passive transcellular diffusion across the intestinal lipid bilayer further limits absorption from the GI lumen. Route consequences: IM injection into the vastus lateralis (for epinephrine in anaphylaxis) provides faster and more reliable peak plasma concentration than SC injection because of greater muscle vascularity; endotracheal instillation (via ET tube in cardiac arrest if IV access unavailable) is an alternative route but with lower and less predictable bioavailability; IV infusion is required for catecholamines used as vasopressors and inotropes. Options B and D are both accurate; D adds the important polarity point and the IM vs SC comparison that is clinically tested.
Option A: Option A is incorrect: molecular weight is not the reason catecholamines cannot be given orally; at 180-220 daltons, catecholamines are well within the size range for passive intestinal absorption (Lipinski's rule of 5 allows up to 500 daltons); the barrier to oral bioavailability is metabolic (COMT in the intestinal wall and hepatic first-pass metabolism), not a size exclusion mechanism.
Option B: Option B is partially correct in identifying intestinal COMT and hepatic MAO as degradative mechanisms; however, Option D is the more complete answer because it adds the critical pharmacokinetic point about ionization — catecholamines are positively charged at physiological pH due to their amino group (pKa ~8.5-9.5), making them polar and poorly absorbed by passive diffusion across lipid membranes; this polarity combined with enzymatic degradation explains mandatory IV administration.
Option C: Option C is incorrect: catecholamines are not degraded by gastric acid; the catechol ring is stable at acidic pH; gastric acid (pH 1-2) does not hydrolyze the dihydroxybenzene ring; the barrier to oral bioavailability is not gastric stability but rather intestinal wall COMT metabolism and hepatic first-pass metabolism after absorption, combined with poor passive absorption due to polarity.
Option E: Option E is incorrect: oral catecholamines do not have acceptable bioavailability; extensive COMT metabolism in the intestinal wall and hepatic first-pass metabolism by both COMT and MAO reduce oral bioavailability to effectively zero for the clinically used catecholamines; no oral epinephrine tablet has been developed with adequate systemic bioavailability for clinical use; the premise of this option is factually incorrect.
9. Epinephrine is the drug of first choice in anaphylaxis. Which of the following correctly identifies the preferred route, site, dose, and concentration of epinephrine for initial anaphylaxis management in an adult?
A) Preferred route: intravenous bolus (IV push); site: antecubital vein; dose: 1 mg (1 mL of 1:1,000 solution); rationale: IV bolus provides the fastest onset of epinephrine action in anaphylactic shock where circulatory compromise may reduce IM absorption; the 1 mg dose is derived from the same dose used in cardiac arrest; IV push epinephrine for anaphylaxis should be the first-line route in all settings including community management.
B) Preferred route: subcutaneous injection; site: deltoid; dose: 0.5 mg; concentration: 1:10,000 solution (0.1 mg/mL); rationale: subcutaneous injection was the original route described by early anaphylaxis treatment protocols; the deltoid provides adequate vascular access through subcutaneous adipose tissue; the 1:10,000 concentration is used to reduce the risk of inadvertent intravascular injection causing cardiac arrhythmias.
C) Preferred route: inhalation; dose: 2.25% racemic epinephrine solution via nebulizer; site: airways; rationale: inhaled epinephrine directly targets the beta-2 bronchial receptors that mediate bronchoconstriction in anaphylaxis; the inhaled route avoids systemic cardiovascular effects (tachycardia, hypertension) because inhaled catecholamines do not reach the systemic circulation in significant quantities; inhaled epinephrine is equivalent to IM epinephrine for anaphylaxis management with a better safety profile.
D) Preferred route: intramuscular injection; site: anterolateral thigh (vastus lateralis); dose: 0.3-0.5 mg in adults; concentration: 1:1,000 solution (1 mg/mL); rationale: IM injection into the anterolateral thigh produces faster and more reliable peak epinephrine plasma concentrations than subcutaneous injection (due to greater vascularity of the vastus lateralis compared to subcutaneous tissue); the 1:1,000 concentration is used for IM injection; standard auto-injectors (EpiPen) deliver 0.3 mg IM for adults and 0.15 mg IM for children under 25 kg; IV administration is reserved for anaphylaxis refractory to IM epinephrine or occurring in a monitored setting with resuscitation equipment immediately available, and requires dilution to a 1:10,000 or greater concentration with careful titration to avoid cardiovascular toxicity.
E) Preferred route: intracardiac injection; site: left ventricle (4th intercostal space, left parasternal); dose: 1 mg of 1:10,000 solution; rationale: intracardiac injection delivers epinephrine directly to cardiac receptors, bypassing the need for systemic circulation and therefore being effective even in the complete cardiovascular collapse of severe anaphylaxis; this route was standard for anaphylactic cardiac arrest before peripheral IV access techniques improved; it remains the recommended first-line route for anaphylaxis in current WAO guidelines for resource-limited settings.
ANSWER: D
Rationale:
The route, site, dose, and concentration specifications for anaphylaxis epinephrine are critical clinical knowledge with patient safety implications. Current international consensus (World Allergy Organization guidelines, ACAAI/AAAAI guidelines, Anaphylaxis Campaign): Preferred route: IM injection; Preferred site: anterolateral mid-thigh (vastus lateralis muscle); the vastus lateralis has higher blood flow than deltoid or subcutaneous adipose tissue, producing faster peak plasma epinephrine concentrations and more reliable pharmacokinetics; studies by Simons et al. using pharmacokinetic sampling confirmed that IM injection into the thigh produces faster Tmax and higher Cmax than either SC injection or IM deltoid injection. Dose: 0.3-0.5 mg in adults (0.01 mg/kg for children, maximum 0.5 mg). Concentration: 1:1,000 solution (1 mg/mL) -- this is the standard epinephrine auto-injector and commercial ampule concentration for IM injection; it must NOT be confused with the 1:10,000 solution (0.1 mg/mL) used for IV administration; giving 1:1,000 solution IV would deliver 10 times the intended dose and risk fatal cardiovascular toxicity. Standard auto-injectors: EpiPen/Auvi-Q 0.3 mg for adults and children over 25 kg; EpiPen Jr/Auvi-Q 0.15 mg for children 15-25 kg. IV epinephrine: reserved for refractory anaphylaxis in a monitored setting; requires dilution to 1:10,000 or greater and careful titration; unmonitored IV bolus epinephrine for anaphylaxis has caused iatrogenic hypertensive emergencies and arrhythmias. SC injection (option B) is no longer preferred over IM due to slower absorption.
Option A: Option A is incorrect: IV bolus epinephrine is not the preferred route for out-of-hospital anaphylaxis; unmonitored IV bolus of 1 mg of 1:1,000 epinephrine (the concentration in auto-injectors) delivers a massive vasoactive dose that has caused fatal hypertensive emergencies and arrhythmias in anaphylaxis patients who did not require IV epinephrine; IM injection into the vastus lateralis delivers 0.3 mg with reliable absorption and a safer peak concentration profile.
Option B: Option B is incorrect: subcutaneous injection is no longer the preferred route; SC injection has slower and more variable absorption than IM injection because cutaneous vasoconstriction (from the epinephrine itself and from anaphylaxis-associated hypotension) reduces SC blood flow and delays systemic absorption; randomized pharmacokinetic studies have demonstrated superior peak plasma concentrations and time-to-peak with IM vastus lateralis injection versus SC deltoid injection.
Option C: Option C is incorrect: inhaled epinephrine via nebulizer is not appropriate for systemic anaphylaxis; nebulized epinephrine delivers drug primarily to the airway mucosa and provides minimal systemic absorption; it cannot reverse anaphylactic shock (which requires systemic alpha-1-mediated vasoconstriction) or systemic urticaria; inhaled racemic epinephrine is used for croup (upper airway edema) not for IgE-mediated anaphylaxis.
Option E: Option E is incorrect: intracardiac epinephrine injection is obsolete and absolutely contraindicated in anaphylaxis; intracardiac injection risks pneumothorax, coronary artery laceration, cardiac tamponade, and refractory arrhythmias; it was abandoned in resuscitation protocols decades ago and has no role in anaphylaxis management; the vastus lateralis IM route provides rapid and effective systemic delivery without these risks.
10. Norepinephrine extravasation during peripheral IV infusion is a recognized complication requiring specific treatment. Which of the following correctly identifies the mechanism of extravasation injury and the pharmacological treatment?
A) Norepinephrine extravasation into perivascular tissue causes injury through beta-1 receptor activation on local fibroblasts and mast cells -- beta-1 activation by extravasated NE produces cAMP-mediated histamine release from mast cells and growth factor release from fibroblasts, causing local inflammation and edema; the treatment is topical hydrocortisone cream applied to the affected skin, which blocks the beta-1-mediated inflammatory cascade.
B) Norepinephrine extravasation produces ischemic tissue necrosis through intense local alpha-1 receptor-mediated vasoconstriction -- extravasated NE activates alpha-1 receptors on local arterioles and capillaries, producing Gq-IP3-calcium-MLCK-mediated vasoconstriction that cuts off blood flow to the affected tissue; the result is progressive ischemic necrosis that can extend well beyond the extravasation site if untreated; treatment: phentolamine (non-selective alpha-1 and alpha-2 antagonist) 5-10 mg dissolved in 10-15 mL of normal saline infiltrated subcutaneously into the affected area as soon as possible; phentolamine competitively blocks the alpha-1 receptors activated by the extravasated NE, reversing the vasoconstriction and restoring local blood flow; topical nitroglycerin paste (an alternative) produces NO-mediated vasodilation downstream of the alpha-1 receptor.
C) Norepinephrine extravasation causes tissue injury through direct catechol ring cytotoxicity -- the catechol nucleus of NE is oxidized by tissue-derived reactive oxygen species to a quinone that alkylates DNA and disrupts cell membrane integrity; this cytotoxic mechanism is receptor-independent and cannot be reversed by alpha-1 antagonists; treatment requires surgical debridement of the affected tissue and wound care; phentolamine infiltration is ineffective because the injury is not mediated by alpha-1 receptor activation.
D) Norepinephrine extravasation produces injury through beta-2 receptor-mediated local vasodilation that paradoxically causes edema -- beta-2 activation in extravasated tissue increases vascular permeability via cAMP-PKA phosphorylation of vascular endothelial junction proteins; the increased permeability allows further NE leak into adjacent tissue spaces, propagating the injury; treatment requires beta-2 blockade with topical propranolol cream.
E) Norepinephrine extravasation is not a clinical concern in modern practice because all NE infusions are administered through central venous catheters; peripheral IV NE administration is absolutely contraindicated and never performed; the phentolamine infiltration protocol for NE extravasation is therefore historical and has no current clinical application.
ANSWER: B
Rationale:
NE extravasation is a recognized and clinically important complication of peripheral IV administration. The mechanism: extravasated NE activates alpha-1 adrenergic receptors (Gq-IP3-Ca2+-MLCK) on local arterioles and capillaries in the perivascular tissue, producing intense vasoconstriction; this vasoconstriction dramatically reduces local blood flow, creating an ischemic environment in the tissue surrounding the infiltration site; without treatment, progressive ischemic necrosis occurs, often resulting in skin sloughing and tissue loss that may require surgical debridement and skin grafting. Treatment: phentolamine (non-selective competitive alpha-1 and alpha-2 antagonist) 5-10 mg in 10-15 mL of normal saline infiltrated into the affected area; phentolamine competitively blocks the alpha-1 receptors on local vessels, reversing the vasoconstriction and restoring tissue perfusion; must be administered within 12 hours of extravasation (earlier is better); the affected skin should be monitored for at least 1-2 hours after treatment for restoration of color and warmth. Alternative: topical nitroglycerin (glyceryl trinitrate) paste applied to the affected area produces NO-mediated vasodilation downstream of the alpha-1 receptor via soluble guanylate cyclase-cGMP-PKG-MLCK dephosphorylation; less well established than phentolamine but useful when phentolamine is unavailable. Prevention: NE should ideally be administered through central venous access; however, peripheral administration is sometimes necessary in emergency situations before central access is available; close monitoring of the IV site for early signs of extravasation is essential.
Option A: Option A is incorrect: NE extravasation injury is not mediated through beta-1 receptor activation on local fibroblasts and mast cells causing cAMP-mediated cytokine release; this is a fabricated mechanism with no pharmacological basis; the actual injury mechanism is alpha-1-mediated severe local vasoconstriction producing tissue ischemia and necrosis, not a beta-1-mediated inflammatory cascade.
Option C: Option C is incorrect: while catechol ring oxidation to quinones is a real chemical phenomenon that can contribute to cellular toxicity in some contexts, it is not the primary mechanism of NE extravasation injury in clinical settings; the dominant and clinically relevant mechanism is alpha-1 receptor-mediated intense local vasoconstriction causing tissue ischemia; phentolamine reversal (alpha-1 blockade) is effective precisely because the mechanism is receptor-mediated vasoconstriction.
Option D: Option D is incorrect: NE extravasation injury is not caused by beta-2-mediated vasodilation producing edema; beta-2 activation produces vasodilation and could theoretically worsen edema, but NE has minimal beta-2 activity and the overwhelming pharmacological effect of extravasated NE in tissue is alpha-1-mediated intense vasoconstriction; describing the injury mechanism as vasodilatory edema is the opposite of the actual pathophysiology.
Option E: Option E is incorrect -- peripheral NE is performed in clinical practice; correct answer is B.
11. Isoproterenol's use in torsades de pointes (TdP) associated with bradycardia is based on a specific pharmacological mechanism. Which of the following correctly identifies that mechanism and explains why amiodarone would be contraindicated in the same scenario?
A) Isoproterenol treats pause-dependent TdP by activating beta-2 receptors on ventricular cardiomyocytes, which produce Gs-cAMP-PKA-mediated phosphorylation and inactivation of the delayed rectifier potassium channels (IKr and IKs) that are responsible for QT prolongation; by inactivating these channels, isoproterenol restores normal action potential duration (APD); amiodarone is contraindicated because it also inactivates IKr and IKs but does so irreversibly (permanent channel phosphorylation), making recovery from TdP impossible once amiodarone is administered.
B) Isoproterenol treats pause-dependent TdP through its beta-1 chronotropic effect on the SA node -- by increasing heart rate, isoproterenol shortens the cycle length (RR interval), which shortens the QT interval (QT interval is rate-dependent: QT decreases as heart rate increases, described by the Bazett formula QTc = QT/sqrt(RR)); eliminating long pauses removes the rate-dependent QT prolongation that creates the conditions for early afterdepolarizations (EADs) and triggered activity (TdP); isoproterenol also activates beta-1 and beta-2 receptors on ventricular myocytes, increasing IKs (the slow delayed rectifier potassium current) via cAMP-PKA-mediated phosphorylation, which accelerates ventricular repolarization and shortens APD; amiodarone is contraindicated because it is a potent IKr (and to a lesser degree IKs) channel blocker, prolonging APD and QT interval and potentially worsening the QT prolongation that is causing the TdP; additionally, amiodarone slows heart rate (through beta and calcium channel blockade), which further lengthens the QT and may worsen pause-dependent arrhythmia.
C) Isoproterenol treats TdP by directly blocking early afterdepolarizations (EADs) at the myocardial cell membrane through its membrane-stabilizing (local anesthetic) property -- isoproterenol blocks voltage-gated sodium channels in the myocardium similarly to lidocaine, reducing the amplitude of EADs below the threshold for triggered beats; increasing heart rate is a secondary effect that reinforces the EAD-blocking mechanism; amiodarone is contraindicated because it reverses isoproterenol's sodium channel block.
D) The isoproterenol-TdP mechanism: isoproterenol increases heart rate by beta-1 SA node activation; the increased heart rate shortens the QT interval and eliminates the pause-dependent cycle length prolongation that triggers EADs; additionally, isoproterenol activates beta-1 ventricular IKs, accelerating repolarization; target heart rate is 90-110 bpm to eliminate pauses; amiodarone is contraindicated in TdP associated with acquired QT prolongation and bradycardia because amiodarone (1) prolongs QT via IKr blockade, (2) slows sinus rate via beta and calcium channel blockade, and (3) may precipitate further QT prolongation in a patient already at arrhythmia risk from QT excess; amiodarone would be appropriate for monomorphic VT or VF, not pause-dependent TdP.
E) Isoproterenol is contraindicated in TdP -- the correct pharmacological treatment for TdP is IV magnesium sulfate (which stabilizes the cardiomyocyte membrane independently of adrenergic receptors) followed by temporary overdrive pacing; isoproterenol is only used in TdP when magnesium fails and pacing is unavailable; the misconception that isoproterenol is the drug of choice for TdP arises from confusing it with its use in heart block (where chronotropy is similarly needed).
ANSWER: A
Rationale:
Torsades de pointes (TdP) is a polymorphic ventricular tachycardia associated with a prolonged QT interval and characteristic beat-to-beat morphological variability. Pause-dependent (bradycardia-dependent, acquired) TdP occurs when prolonged pauses (from bradycardia or post-ectopic compensatory pauses) extend the QT interval, generating early afterdepolarizations (EADs) that trigger runs of TdP. The EAD mechanism: during a prolonged action potential, the L-type calcium current may recover from inactivation and re-activate (generating a second plateau), or the sodium-calcium exchanger (NCX) generates an inward current during calcium overload -- either producing a premature depolarization (EAD) that, if it reaches threshold, triggers a premature beat; in a prolonged QT environment, EADs can generate repetitive triggered beats (TdP). Isoproterenol mechanism in TdP: (1) Beta-1 SA node chronotropy: increases heart rate, shortening the RR interval and correspondingly shortening the QT interval (rate-dependent QT shortening); eliminating long pauses removes the primary trigger for EAD generation; target HR 90-110 bpm; (2) Beta-1/beta-2 ventricular IKs activation: cAMP-PKA-mediated phosphorylation of IKs channels (KCNQ1/KCNE1 complex) increases IKs current, accelerating ventricular repolarization and reducing APD -- directly counteracting the QT prolongation. Amiodarone contraindication in acquired QT prolongation TdP: amiodarone prolongs QT interval (IKr = hERG channel blockade is amiodarone's class III mechanism), further extending the APD and increasing EAD risk; amiodarone also slows heart rate (beta and calcium channel blockade), increasing pause duration; adding amiodarone to acquired QT-related TdP could be fatal. Amiodarone IS appropriate for TdP in the setting of short QT syndrome or TdP related to VF storm. Options B and D are both accurate; B provides the most complete mechanistic account including the IKs activation mechanism.
Option B: Option B is partially correct in identifying that isoproterenol increases heart rate via beta-1 SA node chronotropy and that this shortens the QT interval and eliminates pause-dependent TdP; however, Option A is the correct answer because it provides the more complete mechanistic account, specifically including the IKs (slow delayed rectifier potassium channel) activation mechanism that explains why isoproterenol shortens the QT interval — not merely through cycle length shortening but through direct IKs activation that accelerates cardiac repolarization.
Option C: Option C is incorrect: isoproterenol does not have membrane-stabilizing (local anesthetic) properties and does not block EADs directly at the membrane; membrane stabilization is a property of drugs like propranolol, quinidine, and lidocaine; isoproterenol's mechanism in TdP is through beta-1-mediated chronotropy (increasing heart rate, eliminating the long pauses that trigger EADs) and direct IKs channel activation (shortening the action potential duration and QT interval).
Option D: Option D is partially correct in identifying the mechanism (beta-1 SA node activation increasing heart rate, shortening QT interval, eliminating pause-dependent cycles), but it is less complete than Option A because it does not include the direct IKs channel activation mechanism that contributes to QT shortening beyond simple rate-dependent shortening; Option B is also partially accurate; Option A is the most mechanistically complete single answer.
Option E: Option E is incorrect: isoproterenol is not contraindicated in pause-dependent TdP — it is specifically indicated; the contraindication applies to TdP in the setting of short QT syndrome (where further QT shortening could paradoxically worsen arrhythmia) and to catecholamine-sensitive polymorphic ventricular tachycardia (CPVT), where adrenergic stimulation triggers arrhythmia; for pause-dependent TdP (typically drug-induced QT prolongation or congenital long QT causing bradycardia-dependent triggering), isoproterenol is an appropriate bridging therapy.
12. The PARAMEDIC2 trial (Perkins et al., NEJM 2018) investigated epinephrine in out-of-hospital cardiac arrest. Which of the following correctly identifies the principal finding of the PARAMEDIC2 trial and its pharmacological interpretation?
A) The PARAMEDIC2 trial (n=8014 patients with out-of-hospital cardiac arrest) compared epinephrine 1 mg IV every 3-5 minutes to placebo in a randomized double-blind controlled design; the principal findings were: (1) Epinephrine significantly improved return of spontaneous circulation (ROSC) rate (36.3% vs 11.7%, p less than 0.001) -- confirming the alpha-1-mediated vasoconstrictor mechanism of increasing coronary perfusion pressure during CPR; (2) Epinephrine significantly improved 30-day survival (3.2% vs 2.4%, RR 1.39, p=0.02) -- a statistically significant but modest survival benefit; (3) Epinephrine did NOT significantly improve survival with favorable neurological outcome at 3 months (primary outcome: 2.2% vs 1.9%, p=0.30) -- meaning a higher proportion of survivors in the epinephrine group were in a poor neurological state compared to the placebo group; pharmacological interpretation: epinephrine's alpha-1-mediated peripheral vasoconstriction during CPR may improve coronary perfusion pressure and ROSC but the resulting return to spontaneous circulation may not always translate to intact neurological function, possibly because: the beta-1-mediated post-ROSC tachycardia and increased myocardial oxygen demand may worsen post-resuscitation cardiac dysfunction; the alpha-1-mediated cerebral vasoconstriction (which is not beneficial for brain recovery) may impair cerebral reperfusion; the higher ROSC rate may select for patients with longer no-flow times who are less likely to recover neurological function; these findings have prompted ongoing discussion about optimal epinephrine dosing, timing, and whether neurological outcome should supersede ROSC rate as the primary endpoint for resuscitation drug trials.
B) The PARAMEDIC2 trial demonstrated that epinephrine significantly improved both 30-day survival and neurological outcome at 3 months compared to placebo; the pharmacological interpretation is that epinephrine's beta-1 inotropic mechanism — increasing cardiac contractility and heart rate during CPR — is the primary driver of improved outcomes; the alpha-1 vasoconstrictor component contributes minimally because peripheral vasoconstriction during cardiac arrest primarily diverts blood away from the cerebral circulation, which explains why alpha-1 selective agents like phenylephrine have been shown to be superior to epinephrine in post-PARAMEDIC2 follow-up trials; based on PARAMEDIC2, all major resuscitation guidelines have since increased the recommended epinephrine dose to 2 mg per cycle to maximize the beta-1 inotropic benefit demonstrated in the trial.
C) The PARAMEDIC2 trial found that epinephrine significantly worsened outcomes in all categories -- ROSC, 30-day survival, and neurological outcome -- compared to placebo; the trial definitively established that epinephrine should be removed from cardiac arrest protocols; all current resuscitation guidelines have since removed epinephrine as a recommended drug in cardiac arrest based on PARAMEDIC2 results; the alpha-1 vasoconstrictor mechanism was shown to be harmful rather than beneficial during CPR.
D) The PARAMEDIC2 trial showed that epinephrine improved ROSC and 30-day survival but not neurological outcome; the pharmacological interpretation is that the beta-1 inotropic component of epinephrine (not the alpha-1 vasoconstrictor component) is responsible for improved ROSC -- the inotropic effect restores organized cardiac contractions; however, the beta-1-mediated increased myocardial oxygen demand and tachycardia after ROSC impairs post-resuscitation cardiac function and neurological recovery; the trial results suggest that a selective alpha-1 agonist (without beta-1 activity) might improve ROSC without the post-ROSC beta-1 toxicity; phenylephrine (selective alpha-1) has been proposed as an alternative to epinephrine in cardiac arrest based on this reasoning from PARAMEDIC2.
E) PARAMEDIC2 showed no difference between epinephrine and placebo in any outcome measure -- ROSC, 30-day survival, and neurological outcome were statistically identical between the two groups; the trial definitively established that epinephrine has no pharmacological benefit in cardiac arrest and that the historical belief in epinephrine's CPR benefit was based entirely on animal studies that do not translate to humans; human cardiac tissue does not express the alpha-1 receptors that mediate epinephrine's vasoconstrictive effects in animal models.
ANSWER: A
Rationale:
The PARAMEDIC2 trial (Perkins GD et al., N Engl J Med 2018;379:711-721) is the landmark randomized controlled trial establishing the current evidence base for epinephrine in out-of-hospital cardiac arrest. Trial design: double-blind, randomized, placebo-controlled; 8,014 patients with out-of-hospital cardiac arrest in the UK; epinephrine 1 mg IV every 3-5 minutes per standard protocol versus placebo. Key findings: (1) ROSC: epinephrine significantly improved ROSC (36.3% vs 11.7%); (2) 30-day survival: epinephrine significantly improved survival (3.2% vs 2.4%, RR 1.39, 95% CI 1.06-1.82, p=0.02); (3) Neurological outcome (primary endpoint): no significant difference in survival with favorable neurological outcome at 3 months (2.2% epinephrine vs 1.9% placebo, p=0.30); (4) A higher proportion of survivors in the epinephrine group had poor neurological outcomes (31.0% vs 17.8% in severe neurological impairment category). Pharmacological interpretation: epinephrine's alpha-1-mediated vasoconstriction demonstrably improves coronary perfusion pressure during CPR and ROSC -- the mechanism is validated; however, the higher ROSC rate does not translate proportionally to good neurological survival, suggesting: (a) epinephrine-facilitated ROSC occurs in patients who had prolonged ischemic times and may have sustained irreversible neurological injury; (b) post-ROSC beta-1-mediated tachycardia, increased myocardial oxygen demand, and potential cerebral microvascular effects may impair recovery; the trial did NOT lead to removal of epinephrine from guidelines; epinephrine remains a Class IIb recommendation in AHA/ERC guidelines with acknowledgment that survival benefit exists but neurological outcome benefit is unproven.
Option B: Option B is incorrect on multiple counts: PARAMEDIC2 did not show improved neurological outcome (the primary endpoint was not met); beta-1 inotropy is not the primary mechanism of epinephrine benefit in cardiac arrest (alpha-1 vasoconstriction raising coronary perfusion pressure is); phenylephrine has not been shown superior to epinephrine in any post-PARAMEDIC2 trial; and epinephrine dosing was not changed by PARAMEDIC2 findings.
Option C: Option C is incorrect; epinephrine significantly improved ROSC and 30-day survival in PARAMEDIC2; the trial did not lead to removal of epinephrine from resuscitation guidelines, which continue to recommend it.
Option D: Option D is partially accurate in identifying that beta-1 effects may impair post-ROSC recovery, but incorrectly states that the alpha-1 vasoconstrictor mechanism is responsible for ROSC via inotropic organized contractions — alpha-1 raises coronary perfusion pressure, not cardiac contractility; additionally, phenylephrine has not been established as a superior alternative to epinephrine based on PARAMEDIC2.
Option E: Option E is entirely incorrect; PARAMEDIC2 showed clear and significant differences between epinephrine and placebo in ROSC and 30-day survival; the trial confirmed that alpha-1 receptors mediate the vasoconstrictive benefit of epinephrine in human cardiac arrest.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.